Winton Group’s NovoCure NVCR Stock Holding History

Winton Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,800	Closed	-$166K	–	1307
2025 Q4	$166K	Buy	+12,800	New	+$164K	0.01%	844
2025 Q3	–	Sell	-30,585	Closed	-$544K	–	937
2025 Q2	$544K	Buy	+30,585	New	+$533K	0.03%	575
2019 Q2	–	Sell	-8,765	Closed	-$422K	–	1243
2019 Q1	$422K	Buy	8,765 +1,378	+19%	+$66.3K	0.01%	651
2018 Q4	$247K	Buy	7,387 +1,442	+24%	+$52.7K	0.01%	732
2018 Q3	$312K	Sell	5,945 -505	-8%	-$20.1K	0.01%	803
2018 Q2	$202K	Buy	+6,450	New	+$179K	0.01%	985

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Winton Group's NVCR Position: Q1 2026 in Review

Winton Group sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 12,800 shares — an estimated $166K sold.

Winton Group first reported a position in NVCR in Q2 2018 and held it in 6 quarters. The position peaked at $544K in Q2 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Winton Group reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Winton Group sold 12,800 NovoCure shares in Q1 2026, an estimated $166K.
Winton Group first reported a position in NovoCure in Q2 2018 and held it in 6 quarters.
Winton Group's NovoCure position peaked at $544K in Q2 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.